Savara Inc stock (US80633A1025): fresh IMPALA?2 data at ATS 2026 keeps rare?disease bet in focus
Savara Inc. (SVRA) has released new long-term Phase 3 IMPALA-2 data for its molgramostim aPAP therapy at the ATS 2026 conference, drawing renewed investor interest. The data reinforced the sustained clinical benefit and consistent safety profile of molgramostim, along with positive biomarker findings. This information is crucial for the Nasdaq-listed clinical-stage biopharmaceutical company as it aims for regulatory approval in the rare respiratory disease market.
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Savara Inc. presented new biomarker data from its IMPALA-2 Phase 3 clinical trial of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis (aPAP) at the ATS 2026 International Conference. The data showed that molgramostim significantly improved pulmonary gas transfer and decreased levels of disease-associated biomarkers such as LDH, CYFRA 21-1, and KL-6 compared to placebo. These improvements in biomarkers were strongly correlated with the enhancements in pulmonary gas transfer, indicating the drug's efficacy in managing aPAP.
Savara presents biomarker data from molgramostim trial at ATS
Savara Inc. presented biomarker data from its IMPALA-2 Phase 3 clinical trial at the ATS 2026 International Conference, demonstrating statistically significant improvements in pulmonary gas transfer. The trial showed correlations between improvements in lung function and decreases in specific biomarkers. These findings, along with recent regulatory advancements, underline the potential of molgramostim for autoimmune pulmonary alveolar proteinosis (aPAP).
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Savara Inc. presented new biomarker data from its IMPALA-2 Phase 3 clinical trial of molgramostim for autoimmune pulmonary alveolar proteinosis (aPAP) at the ATS 2026 International Conference. The data showed that molgramostim significantly decreased biomarker levels associated with aPAP disease severity, such as LDH, CYFRA 21-1, and KL-6. These reductions were strongly correlated with improvements in pulmonary gas transfer, indicating the drug's effectiveness in addressing the underlying pathology of the rare lung disease.
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. presented long-term efficacy and safety data from the ongoing IMPALA-2 Phase 3 clinical trial's open-label extension for molgramostim inhalation solution in autoimmune pulmonary alveolar proteinosis (aPAP) at the ATS 2026 International Conference. The data showed continuous improvements in pulmonary gas transfer and respiratory health-related quality of life for patients receiving molgramostim, including those who had previously received placebo. Molgramostim was generally well tolerated, with high patient retention, supporting its potential as an effective treatment for aPAP.
48 weeks on Savara's aPAP drug show sustained lung and quality-of-life gains
Savara Inc. presented positive long-term efficacy and safety data from the first 48 weeks of the ongoing open-label extension of its IMPALA-2 Phase 3 clinical trial for molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP). The data, presented at the ATS 2026 International Conference, showed sustained improvements in lung function (DLco%) and respiratory health-related quality of life (SGRQ-T and SGRQ-A scores) for patients who continued on molgramostim, and significant improvements for those who crossed over from placebo to molgramostim. The drug was found to be well-tolerated, with a high patient retention rate, suggesting its potential as an effective long-term treatment option for aPAP.
SVRA: MOLBREEVI nears approval for aPAP, backed by strong data and robust commercial preparation
MOLBREEVI, an inhaled GM-CSF therapy developed by Savara, Inc. (SVRA) for aPAP, is approaching potential approval with strong clinical data and significant payer support. The company is preparing for a U.S. launch by expanding diagnosis and raising awareness, while also considering future international opportunities. This information is based on an H.C. Wainwright investor conference audio transcript from May 19, 2026.
Savara Inc stock (US80633A1025): higher losses, trial progress and elevated short interest
Savara Inc. is attracting investor attention due to increased quarterly losses but also positive clinical trial results for its aPAP drug and significant short interest. The company's net loss widened to approximately $37.28 million in Q1 2026, yet its aPAP therapy shows promise in improving exercise capacity, driving a 64% stock increase over the past year. High short interest, at 14.24% of the free float, indicates a complex risk-reward profile for the clinical-stage biopharmaceutical firm.
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. presented new exercise capacity data from its IMPALA-2 Phase 3 clinical trial of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis (aPAP) at the ATS 2026 International Conference. The data showed that molgramostim significantly improved both distance walked and duration of exercise in aPAP patients compared to placebo over 48 weeks. These findings reinforce the potential clinical benefits of molgramostim for patients with this rare respiratory disease.
Savara reports exercise improvements in aPAP drug trial
Savara Inc. announced positive results from its IMPALA-2 Phase 3 clinical trial for molgramostim, showing significant improvements in exercise distance and duration for patients with autoimmune pulmonary alveolar proteinosis (aPAP). The data, presented at the American Thoracic Society International Conference, indicates potential real-world functional benefits for aPAP patients and has contributed to Savara's strong stock performance. Wall Street analysts maintain a bullish outlook on Savara, despite a recent FDA extension for molgramostim's review period, reinforcing confidence in its regulatory approval and market potential.
Savara reports exercise improvements in aPAP drug trial By Investing.com
Savara Inc. announced positive results from its IMPALA-2 Phase 3 clinical trial for molgramostim, showing significant improvements in exercise distance and duration for patients with autoimmune pulmonary alveolar proteinosis (aPAP). The company's stock has seen a 64% return over the past year, and Wall Street analysts remain bullish, with price targets ranging from $9 to $16 per share. The FDA recently extended its review period for molgramostim, with a decision expected by November 22, 2026.
Is Savara’s Rising Quarterly Loss Reshaping the Risk‑Reward Profile for Investors in SVRA?
Savara Inc. reported a significant increase in its first-quarter 2026 net loss, rising to US$37.28 million from US$26.64 million a year earlier, with basic loss per share at US$0.15. This widening loss, combined with the delayed FDA review for MOLBREEVI, intensifies concerns about the company's financial sustainability and need for additional capital. The article suggests that Savara's investment narrative now heavily relies on the success of MOLBREEVI's regulatory path and careful management of increasing quarterly losses.
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. presented new exercise capacity data from its IMPALA-2 Phase 3 clinical trial of molgramostim for autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the ATS 2026 International Conference. The data showed that molgramostim improved both the distance walked and duration of exercise in aPAP patients compared to placebo. These findings reinforce previously reported improvements in peak metabolic equivalents, suggesting significant clinical benefits for patients.
Is Savara’s Rising Quarterly Loss Reshaping the Risk‑Reward Profile for Investors in SVRA?
Savara Inc. reported a significant increase in its net loss for Q1 2026, reaching US$37.28 million, up from US$26.64 million a year earlier, and a higher basic loss per share of US$0.15. This widening loss, coupled with the reliance on the future regulatory approval of MOLBREEVI and a recent FDA review extension, intensifies concerns about the company's funding and risk-reward balance for investors. Analysts suggest potential overvaluation of Savara shares, stressing the importance of regulatory timing and the company's ability to manage rising quarterly losses.
Savara Inc stock (US80633A1025): respiratory disease specialist after latest clinical and funding up
Savara Inc. (SVRA) is a clinical-stage biotech company focused on rare lung diseases, with its investment case centered on the development of molgramostim for autoimmune pulmonary alveolar proteinosis (aPAP). The company recently provided clinical data and funding updates, highlighting its strategy for late-stage clinical trials, regulatory approvals, and potential commercialization, either independently or through partnerships. Savara funds its operations through equity offerings and non-dilutive funding as it currently generates no product revenue, emphasizing careful cash management for its clinical program.
Is Savara’s Rising Quarterly Loss Reshaping the Risk‑Reward Profile for Investors in SVRA?
Savara Inc. reported a significant increase in its net loss for the first quarter of 2026, reaching US$37.28 million, up from US$26.64 million a year earlier. This widening loss, coupled with the extended FDA review for MOLBREEVI, intensifies concerns about the company's funding and impact on its risk-reward profile for investors. The article highlights the need for investors to critically assess Savara's financial health, especially given potential overvaluation and the reliance on future regulatory approvals to justify ongoing cash burn.
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
Savara Inc. announced its participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference. Members of their management team will present in a fireside chat on Tuesday, May 19th at 10:00am ET at the NASDAQ headquarters. A live webcast and subsequent replay will be available on the company's corporate website.
Savara stock (US80633A1025): Rare disease biotech gains 3.74% on trading momentum
Savara Inc. (SVRA) shares rose by 3.74% on May 13, 2026, closing at $5.27, driven by renewed investor interest in its rare disease pipeline. The clinical-stage biopharmaceutical company, focused on rare respiratory diseases, is advancing molgramostim, its lead candidate, through Phase 3 trials for autoimmune pulmonary alveolar proteinosis (aPAP). While analyst sentiment is mixed, with price targets varying widely, the company's focus on orphan diseases and potential for regulatory incentives offer significant upside for investors with higher risk tolerance.
Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, Vs. FactSet Est of $-0.13 Loss
Savara (SVRA) reported a Q1 per share loss of $-0.15, which was wider than the FactSet estimate of a $-0.13 loss. The company's financial performance missed analyst expectations for the quarter.
Savara Reports First Quarter Financial Results and Provides Business Update
Savara Inc. reported its first-quarter 2026 financial results, showing a net loss of $37.3 million, an increase from the previous year, primarily due to higher R&D and G&A expenses related to its MOLBREEVI program and increased share-based compensation. The company achieved significant regulatory milestones for MOLBREEVI, including BLA filing acceptance by the FDA with a PDUFA date of November 22, 2026, and validated MAAs by the EMA and MHRA. Savara remains well-capitalized with approximately $203 million in cash and short-term investments, plus access to an additional $150 million in non-dilutive capital upon FDA approval, positioning it for the global commercial launch of MOLBREEVI for autoimmune PAP.
Savara Reports First Quarter Financial Results and Provides Business Update
Savara Inc. reported its first-quarter 2026 financial results, including a net loss of $37.3 million, and provided a business update highlighting significant progress in the MOLBREEVI development program for autoimmune PAP. The company announced regulatory milestones with the FDA BLA filing and EMA/MHRA marketing authorization applications, alongside an upcoming presentation of new Phase 3 IMPALA-2 data. Savara also emphasized its strong financial position with substantial cash and access to non-dilutive capital, ensuring readiness for a global commercial launch.
Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, vs. FactSet Est of $-0.13 Loss
Savara Inc. (SVRA) reported a Q1 per-share loss of $-0.15, which is wider than the FactSet estimate of a $-0.13 loss. The clinical-stage biopharmaceutical company focuses on rare respiratory diseases, with its lead program, molgramostim nebulizer solution, in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP).
Savara Q1 net loss widens on higher R&D costs
Savara's first-quarter net loss has widened due to increased research and development costs. The article, sourced from Reuters via Refinitiv, is a concise report on the company's financial performance for Q1.
Potential first autoimmune PAP treatment faces Nov. 22 FDA decision
Savara Inc. reported a Q1 2026 net loss of $37.3 million, an increase from $26.6 million in Q1 2025, primarily due to higher R&D and G&A expenses. The company is advancing its lead program, MOLBREEVI, for autoimmune Pulmonary Alveolar Proteinosis (PAP), with an FDA PDUFA target action date of November 22, 2026, and expects regulatory decisions in Europe and the UK in Q4 2026 and Q1 2027. Savara states it is well-capitalized for a global commercial launch with approximately $203 million in cash and potential access to an additional $150 million upon FDA approval.
Savara (SVRA) deepens Q1 2026 loss while pushing MOLBREEVI toward key FDA and EMA decisions
Savara (SVRA) reported a widened net loss of $37.3 million in Q1 2026, compared to $26.6 million in Q1 2025, primarily due to increased research and development and stock-based compensation costs as it advances its lead drug candidate, MOLBREEVI. The company maintains solid liquidity with $38.8 million in cash and $164.0 million in short-term investments, supporting ongoing development and regulatory pursuits. MOLBREEVI is progressing towards key regulatory decisions, with the FDA granting Priority Review and setting a PDUFA date of November 22, 2026, while EMA and MHRA have also validated marketing applications with decisions anticipated in late 2026 and early 2027.
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
Savara Inc. announced its participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference. Members of the management team will present in a fireside chat on May 19th at 10:00 AM ET at the NASDAQ headquarters in New York, NY. A webcast of the presentation will be available on the company's website.
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
Savara Inc. will participate in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on May 19th, 2026, at NASDAQ headquarters in New York, NY. The company, which focuses on rare respiratory diseases and has MOLBREEVI in Phase 3 development for autoimmune PAP, will host a fireside chat at 10:00 AM ET. A webcast of the event will be available on Savara's corporate website.
Rare lung disease biotech Savara in Nasdaq investor chat
Savara Inc. (Nasdaq: SVRA), a biopharmaceutical company specializing in rare respiratory diseases, announced its management team will attend the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference. They will participate in a fireside chat on May 19th at the NASDAQ headquarters. A live webcast and replay will be available on the company’s corporate website for 90 days.
Swedbank AB Has $5.13 Million Position in Savara Inc. $SVRA
Swedbank AB significantly increased its stake in Savara Inc. by 54.5% in the fourth quarter, bringing its total holding to 850,000 shares valued at approximately $5.13 million. Despite Savara reporting a slightly wider-than-expected loss of $0.13 per share, institutional ownership remains high at nearly 88%, and analysts maintain a "Moderate Buy" consensus rating with a target price of $9.13. Other institutional investors also adjusted their positions in the rare respiratory disease biopharmaceutical company.
Nan Fung Trinity HK Ltd. Takes $10.18 Million Position in Savara Inc. $SVRA
Nan Fung Trinity HK Ltd. recently acquired a significant new stake in Savara Inc. (NASDAQ:SVRA), purchasing 1,688,500 shares valued at approximately $10.18 million. This investment highlights strong institutional interest, with other major firms also increasing their holdings, bringing total institutional ownership to 87.93%. Despite a recent slight earnings miss, analysts maintain a "Moderate Buy" rating for Savara, with an average target price of $9.13 compared to its current trading price of $5.23.
Savara Inc. $SVRA Position Boosted by F m Investments LLC
F m Investments LLC significantly increased its stake in Savara Inc. (NASDAQ:SVRA) by 56.5% during the fourth quarter, bringing its total ownership to 678,813 shares valued at approximately $4.1 million. This increase is part of a broader trend of high institutional ownership, with 87.93% of Savara's stock held by institutions, including Vanguard and Swedbank, which also boosted their positions. Despite a recent quarterly loss that slightly missed estimates, analyst sentiment for Savara remains moderately positive, with a consensus "Moderate Buy" rating and an average price target of $9.13.
SVRA Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for SVRA, including past and future revenue and EPS estimates. It details how the stock price typically reacts to earnings reports and the impact of forecast revisions on investor sentiment. Investors are advised to consider the relationship between earnings forecasts and stock price movements, with potential buying opportunities indicated by positive revisions amid temporary price dips.
Savara faces earnings test ahead of crucial FDA decision By Investing.com
Savara Inc. is set to report its first-quarter earnings, with analysts expecting a loss of $0.12 per share on zero revenue. This report is critical as the company approaches a pivotal FDA decision for its lead drug candidate, MOLBREEVI, which could transform it into a commercial player in rare lung diseases. Investors will be closely watching Savara's cash position, financing strategy, regulatory updates, and commercial preparation milestones.
Savara Grants Equity Awards to 24 New Employees
Savara Inc. recently granted equity inducement awards to 24 new employees on April 14, 2026, as an incentive to join the company. These awards include stock options, restricted stock units, and performance stock units, all vesting under specific conditions such as time or achievement of quarterly revenue targets. Savara is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases.
FDA Extends Review of Savara’s Molgramostim Application to November
The FDA has extended its review of Savara Inc.'s biologics license application for molgramostim by three months, setting a new target action date of November 22, 2026. This extension was triggered after the FDA deemed Savara's responses to recent information requests as a major amendment. Molgramostim is under Priority Review for the treatment of autoimmune pulmonary alveolar proteinosis and has various fast-track designations.
Savara to Present Molgramostim Data at ATS 2026 Conference
Savara Inc. will present new clinical data on its investigational therapy molgramostim at the ATS International Conference in Orlando, Florida, from May 17–20, 2026. The presentations will include results from the Phase 3 IMPALA-2 clinical trial for autoimmune pulmonary alveolar proteinosis (aPAP), with one oral presentation focusing on exercise improvements and two poster sessions covering long-term efficacy, safety, and biomarker relationships. The company will also host an industry theater session on aPAP.
Savara’s FDA Review Extension Keeps Molgramostim Thesis Intact But Delayed
The FDA has extended its Priority Review for Savara's molgramostim BLA by three months due to a major amendment, but without citing new safety, efficacy, or manufacturing concerns. This extension maintains the company's core thesis for its lead product candidate for autoimmune pulmonary alveolar proteinosis, despite delaying the regulatory timeline. Investors should monitor upcoming FDA communications and the company's cash burn given its minimal revenue and recent shareholder dilution.
[ARS] Savara Inc SEC Filing
This article announces an ARS filing by Savara Inc (SVRA) on April 24, 2026, categorized with low impact and neutral sentiment. The filing is available as a PDF document on SEC EDGAR. The article also provides a brief overview of Savara Inc's stock data, recent news, and other SEC filings.
Savara (NASDAQ: SVRA) seeks big share boost and equity plan expansion
Savara Inc. is seeking stockholder approval for several key proposals at its 2026 virtual annual meeting, including doubling its authorized common shares from 300 million to 600 million and increasing its 2024 Omnibus Incentive Plan share pool by 18.9 million. These measures aim to provide financial flexibility for future capital raises, strategic transactions, and equity-based compensation as the company advances its lead drug candidate, MOLBREEVI, through regulatory reviews in the U.S., EU, and UK. The company recently completed a $149.5 million equity raise, a $75 million royalty funding agreement, and secured additional debt capacity, underscoring its focus on strengthening its financial position ahead of potential MOLBREEVI approvals.
Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at Oppenheimer
Oppenheimer has initiated coverage on Savara (NASDAQ:SVRA) with an "Outperform" rating and an $11.00 price target, suggesting a significant upside. Analyst sentiment for Savara is generally positive, with an average rating of "Moderate Buy" and an average price target of $9.13 from MarketBeat data. Savara, a clinical-stage biopharmaceutical company, is currently trading at $5.04, with its lead candidate, Molgradex, under regulatory review for autoimmune pulmonary alveolar proteinosis.
Savara Inc. (NASDAQ:SVRA) Given Average Recommendation of "Moderate Buy" by Brokerages
Savara Inc. (NASDAQ:SVRA) has received a consensus "Moderate Buy" rating from nine brokerages, with an average 12-month price target of $9.00. The biopharmaceutical company, which focuses on rare respiratory diseases, is currently trading at $5.61 with a market capitalization of $1.15 billion. Analysts expect an EPS of approximately -0.48 for the current year.
Savara Announces New Employment Inducement Grant - April 17, 2026
Savara Inc. announced inducement grants to 24 new employees, consisting of options to purchase 18,500 shares of common stock, restricted stock units covering 141,000 shares, and performance stock units covering 85,000 shares. These grants, made on April 14, 2026, were issued under the company's 2021 Inducement Equity Incentive Plan to attract new talent. Each grant has specific vesting conditions tied to continued employment and, for PSUs, the achievement of a specified revenue target.
FY2026 EPS Estimates for Savara Decreased by Lifesci Capital
Lifesci Capital has reduced its FY2026 EPS estimate for Savara (NASDAQ:SVRA) to ($0.52) from ($0.48), falling below the consensus of ($0.45). The firm also projects Q4 2026 EPS at ($0.14). Despite mixed analyst coverage including buy, hold, and sell ratings, MarketBeat data indicates a "Moderate Buy" consensus rating with a $9.00 target price for Savara, whose shares currently trade around $5.78.
Savara Inc stock (US80633A1025): Why does its rare disease focus matter more now for investors?
Savara Inc. is a biotech company focused on developing therapies for rare pulmonary diseases, particularly molgramostim for autoimmune pulmonary alveolar proteinosis (aPAP) and AeroVanc for MRSA lung infections in cystic fibrosis. The company's strategy relies on high-value, low-competition markets with orphan drug designations offering market exclusivity and pricing power. Savara aims for FDA approval and market launch of its late-stage candidates, which could provide significant returns for investors given the underserved medical needs and regulatory tailwinds for orphan drugs.
Savara Says UK Regulator Accepts MOLBREEVI Application
Savara Inc. announced that the U.K.'s Medicines and Healthcare products Regulatory Agency accepted its marketing authorization application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis, initiating an accelerated 150-day review. This application joins existing reviews in the U.S. and Europe, with decisions expected across all regions within the next 12 months. MOLBREEVI has received multiple regulatory designations, including Fast Track and Breakthrough Therapy status in the United States.
How Investors Are Reacting To Savara (SVRA) FDA Priority Review Extension For Molgramostim In Autoimmune PAP
Savara Inc. recently announced that the FDA has extended the Priority Review for its molgramostim BLA for autoimmune PAP by three months, moving the PDUFA target action date to November 22, 2026. This extension is due to the company submitting additional information, not concerns about safety, efficacy, or manufacturing, suggesting a procedural rather than fundamental issue. Investors are assessing how this delay impacts Savara's investment narrative, particularly concerning regulatory progress and the commercial viability of its single-asset rare-disease therapy.
Savara Announces New Employment Inducement Grant
Savara Inc. announced inducement awards to 24 new employees on April 14, 2026, consisting of options, restricted stock units (RSUs), and performance stock units (PSUs). These equity awards were granted under the company's 2021 Inducement Equity Incentive Plan, as permitted by NASDAQ rules, to incentivize new hires. Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, with its lead program MOLBREEVI* in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Savara Announces New Employment Inducement Grant
Savara Inc., a clinical-stage biopharmaceutical company, announced new employment inducement awards granted to 24 new employees on April 14, 2026. These awards include options to purchase 18,500 shares, restricted stock units (RSUs) covering 141,000 shares, and performance stock units (PSUs) covering 85,000 shares of the company’s common stock. The grants were made under the Savara Inc. 2021 Inducement Equity Incentive Plan, to incentivize employment, with specific vesting schedules tied to continued employment and company performance.
Savara Announces New Employment Inducement Grant
Savara Inc. announced that its Compensation Committee granted inducement awards to 24 new employees on April 14, 2026. These awards include options to purchase 18,500 shares, restricted stock units covering 141,000 shares, and performance stock units covering 85,000 shares of the company’s common stock. The grants were made under the company's 2021 Inducement Equity Incentive Plan, in accordance with NASDAQ Listing Rules, as an inducement for employment.
How Investors Are Reacting To Savara (SVRA) FDA Priority Review Extension For Molgramostim In Autoimmune PAP
Savara Inc. recently announced a three-month extension of the FDA's Priority Review for its molgramostim BLA, moving the PDUFA date to November 22, 2026. This delay, attributed to additional submitted information rather than safety or efficacy concerns, indicates a procedural rather than fundamental issue. The extension impacts the timing of a key catalyst but does not significantly alter the investment thesis focused on the single-asset rare-disease therapy.
